Home Tags

View the Latest: Over-the-Counter Contraceptives

Filter

List Grid

1 - 10 of 12 Results

  • Over-the-Counter Oral Contraceptive Pills

    Issue Brief

    Oral contraceptives are the most commonly used method of reversible contraception in the U.S. In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.

  • Pharmacies as an Access Point for Expanding Contraceptive Care: A Geographic Analysis

    Issue Brief

    In this brief, we explore avenues for expanding hormonal contraceptive care and supplies through pharmacies, as well as how and where pharmacies and pharmacists may be positioned to fill gaps in contraceptive care where there are few brick-and-mortar family planning providers, as well as the challenges in expanding these pathways.

  • Emergency Contraception

    Fact Sheet

    This fact sheet reviews current national and state policies around Emergency Contraception, including methods, patient awareness, access and availability, and insurance coverage. Among methods discussed are ulipristal acetate (ella), intrauterine devices (copper IUDs and levonorgestrel IUDs), and progestin-based pills (Plan B and Next Choice).

  • 3 Charts: The Cost and Coverage of Opill—the First FDA-approved Over-the-Counter Daily Oral Contraceptive Pill in the United States 

    News Release

    The first FDA-approved over-the-counter daily oral contraceptive pill in the United States— Perrigo’s Opill— is now available for pre-order at major online retailers and will soon be available in stores. Although the new over-the-counter pill could broaden access to contraceptive options in the United States, KFF research suggests consumers are likely to face some hurdles if they seek to have their plan cover the costs. For example, while federal policy requires most private health insurance…

  • KFF Examines Key Considerations for the Implementation of Insurance Coverage for Over-the-Counter Contraceptives

    News Release

    With federal regulators seeking public input on the potential benefits, costs, and implementation considerations of requiring private health insurance plans to cover over-the-counter preventive products without a prescription, a new KFF post explores the issues relevant to covering over-the-counter contraceptives. These contraceptives include Opill, the first daily oral contraceptive pill to receive FDA approval for over-the-counter availability. The analysis draws on the lessons learned from KFF staff interviews with more than 80 key players nationally…

  • Considerations for Covering Over-the-Counter Contraception

    Policy Watch

    In October 2023, the Departments of the Treasury, Labor, and Health and Human Services issued a request for information to gather public input about the potential benefits, costs, and implementation considerations of requiring private health insurance plans to cover OTC preventive services and supplies without a prescription. This policy watch addresses key considerations for the implementation of insurance coverage for non-prescribed OTC contraceptives based on the lessons learned from KFF’s 2023 study of Insurance Coverage…

  • KFF Examines Challenges in Navigating Coverage for Opill, the First Over-the-Counter Daily Oral Contraceptive Pill, Coming to Market Next Year 

    News Release

    As Opill—the first over-the-counter daily oral contraceptive pill in the United States—is expected to be available for purchase in early 2024, new research conducted by KFF examines barriers to its accessibility for consumers and challenges in providing insurance coverage for it. Based on interviews with nearly 80 representatives from private insurance plans, state Medicaid programs, chain pharmacies, and other key groups, the report provides a deeper view into the operational challenges in expanding access to…